Finding new ways to treat melanoma that resists current therapies
Combination Therapies to Defeat Melanoma Resistance
This study is looking at why advanced melanoma sometimes doesn't respond to current treatments, with the goal of finding new ways to make those treatments work better for patients like you.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10878830 on NIH RePORTER |
What this research studies
This research investigates how advanced melanoma can resist existing targeted therapies and immunotherapies. It aims to identify the vulnerabilities in melanoma cells that lead to resistance, allowing for the development of new combination therapies. The research involves studying different genetic and molecular mechanisms that contribute to this resistance and testing new treatment strategies in preclinical models. Patients may benefit from insights that could lead to more effective treatment options for melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced melanoma, particularly those whose tumors have shown resistance to existing treatments.
Not a fit: Patients with early-stage melanoma or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with melanoma that no longer respond to current therapies.
How similar studies have performed: Other research has shown promise in targeting resistance mechanisms in melanoma, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Ribas, Antoni — University of California Los Angeles
- Study coordinator: Ribas, Antoni
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.